Immunic board designee granted 25K stock options
BVF-affiliated entities report a new grant of 25,370 IMMUNIC stock options linked to their board representative, vesting over one year at a $10.12 exercise price.
Rhea-AI Filing Summary
IMMUNIC, INC. (IMUX) reported that investment entities affiliated with Biotechnology Value Fund received a grant of 25,370 stock options on September 16, 2026, indirectly attributable to their board designee, R. Thorvald Nagel. The options have an exercise price of $10.12 per share, vest in monthly increments over one year from the grant date, and expire on September 16, 2036.
The reporting entities and Mark N. Lampert file jointly and each disclaims beneficial ownership except to the extent of pecuniary interest. A prior one-for-ten reverse stock split of IMMUNIC common stock was effective April 27, 2026, and the economic benefit from any sale of shares issuable upon exercise of these options is obligated to be transferred to BVF Partners L.P.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 25,370 shares
Grant/Award
4 txns
Insider
BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N
Role
Director | Director | Director | Director | Director | Director | Director | Director | Director | Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option F1, F6, F7 | 25,370 | $0.00 | $0.00 |
| holding | Common Stock, $0.0001 par value F1, F2, F3 | -- | -- | -- |
| holding | Common Stock, $0.0001 par value F1, F2, F4 | -- | -- | -- |
| holding | Common Stock, $0.0001 par value F1, F2, F5 | -- | -- | -- |
Holdings After Transaction:
Stock Option — 25,370 contracts (Indirect, See footnote);
Common Stock, $0.0001 par value — 759,067 shares (Direct)
Footnotes (7)
- F1. This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
- F2. Reflects a one-for-ten reverse stock split of the Issuer's issued and outstanding Common Stock, effective as of April 27, 2026 (the "Stock Split").
- F3. Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
- F4. Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
- F5. Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
- F6. The option vests in monthly increments over a period of one year from the grant date.
- F7. Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and R. Thorvald Nagel, who serves on the Issuer's board of directors and as a Principal of Partners, pursuant to which Mr. Nagel is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Nagel disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
Key Figures
Stock options granted: 25,370 options
Exercise price: $10.12 per share
Option expiration date: September 16, 2036
+3 more
6 metrics
Stock options granted
25,370 options
Grant to BVF-affiliated entities dated September 16, 2026
Exercise price
$10.12 per share
Exercise price of the 25,370 IMMUNIC stock options
Option expiration date
September 16, 2036
Expiration of the granted IMMUNIC stock options
Vesting period
12 months
Options vest in monthly increments over one year from September 16, 2026
Reverse stock split ratio
1-for-10
Reverse stock split of IMMUNIC common stock effective April 27, 2026
Reverse stock split effective date
April 27, 2026
Date IMMUNIC’s one-for-ten reverse stock split became effective
Key Terms
one-for-ten reverse stock split, beneficial ownership, pecuniary interest, director by deputization, +1 more
5 terms
one-for-ten reverse stock split financial
"Reflects a one-for-ten reverse stock split of the Issuer's issued"
beneficial ownership financial
"Each of the Reporting Persons disclaims beneficial ownership of the"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest"
director by deputization regulatory
"may be deemed to be a director by deputization of the Issuer"
indirect ownership financial
"The option was reported as indirectly owned with nature of ownership"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did IMUX report involving BVF-affiliated entities?
IMMUNIC, INC. reported that BVF-affiliated entities received a grant of 25,370 stock options on September 16, 2026. These options relate to the service of R. Thorvald Nagel on IMMUNIC’s board and are reported as indirectly owned through BVF Partners L.P. and related entities.
What is the exercise price and term of the new IMUX stock options?
The granted IMMUNIC stock options have an exercise price of $10.12 per share and expire on September 16, 2036. According to the disclosure, the options vest in monthly increments over one year from the September 16, 2026 grant date.
How do the BVF entities and Mark N. Lampert describe their ownership of IMUX securities?
Biotechnology Value Fund entities and Mark N. Lampert state that they file jointly and disclaim beneficial ownership of the IMMUNIC securities except to the extent of their pecuniary interest in them, as described in the joint reporting footnote.
What arrangement affects the economic benefit from the IMUX option grant?
R. Thorvald Nagel, a Principal of BVF Partners L.P. and IMMUNIC director, is obligated by agreement to transfer the economic benefit, if any, from sales of shares issuable upon exercise of the reported options to BVF Partners L.P., giving BVF entities a pecuniary interest.
Did IMMUNIC disclose a recent reverse stock split in this Form 4?
Yes. The filing notes a one-for-ten reverse stock split of IMMUNIC’s issued and outstanding common stock, effective April 27, 2026. This split affects how the reported common stock holdings are reflected but does not change the option grant amount itself.
Were the IMUX insider transactions reported under a Rule 10b5-1 trading plan?
No. The filing’s Rule 10b5-1 checkbox is not marked as affirming that the transactions were made under a Rule 10b5-1 trading plan, and there is no footnote stating that this option grant was executed pursuant to such a plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
